These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26517216)

  • 1. Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.
    Sobreira E; Pena-Pereira MA; Eckeli AL; Sobreira-Neto MA; Chagas MH; Foss MP; Cholerton B; Zabetian CP; Mata IF; Tumas V
    Arq Neuropsiquiatr; 2015 Nov; 73(11):929-33. PubMed ID: 26517216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.
    Lucza T; Karádi K; Kállai J; Weintraut R; Janszky J; Makkos A; Komoly S; Kovács N
    Behav Neurol; 2015; 2015():983606. PubMed ID: 26078489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addenbrooke's Cognitive Examination validation in Parkinson's disease.
    Reyes MA; Perez-Lloret S; Roldan Gerschcovich E; Martin ME; Leiguarda R; Merello M
    Eur J Neurol; 2009 Jan; 16(1):142-7. PubMed ID: 19049504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Zabetian CP; Quinn J; Edwards KL; Leverenz JB; Montine T; Cholerton B; Poston KL
    Mov Disord; 2019 Feb; 34(2):285-291. PubMed ID: 30776152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
    Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
    Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Portuguese version of Addenbrooke's Cognitive Examination III in mild cognitive impairment and dementia.
    Peixoto B; Machado M; Rocha P; Macedo C; Machado A; Baeta É; Gonçalves G; Pimentel P; Lopes E; Monteiro L
    Adv Clin Exp Med; 2018 Jun; 27(6):781-786. PubMed ID: 29790690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease.
    Kaszás B; Kovács N; Balás I; Kállai J; Aschermann Z; Kerekes Z; Komoly S; Nagy F; Janszky J; Lucza T; Karádi K
    Parkinsonism Relat Disord; 2012 Jun; 18(5):553-6. PubMed ID: 22405839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of the Addenbrooke's Cognitive Examination - III (ACE-III), Mini-ACE, Mini-Mental State Examination, Montreal Cognitive Assessment, and Hasegawa Dementia Scale-Revised for detecting mild cognitive impairment and dementia.
    Senda M; Terada S; Takenoshita S; Hayashi S; Yabe M; Imai N; Horiuchi M; Yamada N
    Psychogeriatrics; 2020 Mar; 20(2):156-162. PubMed ID: 31448862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests.
    Matias-Guiu JA; Cortés-Martínez A; Valles-Salgado M; Rognoni T; Fernández-Matarrubia M; Moreno-Ramos T; Matías-Guiu J
    Int Psychogeriatr; 2017 Jan; 29(1):105-113. PubMed ID: 27682860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and therapy for neurocognitive disorders in Parkinson's disease].
    Lucza T; Karádi K; Komoly S; Janszky J; Kállai J; Makkos A; Kovács M; Weintraut R; Deli G; Aschermann Z; Kovács N
    Orv Hetil; 2015 Jun; 156(23):915-26. PubMed ID: 26027599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales.
    Gasser AI; Calabrese P; Kalbe E; Kessler J; Rossier P
    Rev Neurol (Paris); 2016 Feb; 172(2):138-45. PubMed ID: 26494570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.
    Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W
    Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia.
    Matteau E; Dupré N; Langlois M; Provencher P; Simard M
    J Geriatr Psychiatry Neurol; 2012 Jun; 25(2):100-6. PubMed ID: 22689702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination-Revised in the diagnosis of dementia.
    Crawford S; Whitnall L; Robertson J; Evans JJ
    Int J Geriatr Psychiatry; 2012 Jul; 27(7):659-69. PubMed ID: 22068971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M
    Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addenbrooke's cognitive examination-revised: normative and accuracy data for seniors with heterogeneous educational level in Brazil.
    César KG; Yassuda MS; Porto FHG; Brucki SMD; Nitrini R
    Int Psychogeriatr; 2017 Aug; 29(8):1345-1353. PubMed ID: 28511735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia.
    Galtier I; Nieto A; Lorenzo JN; Barroso J
    J Clin Exp Neuropsychol; 2016; 38(1):40-50. PubMed ID: 26602176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairment in early-stage non-demented Parkinson's disease patients.
    Pfeiffer HC; Løkkegaard A; Zoetmulder M; Friberg L; Werdelin L
    Acta Neurol Scand; 2014 May; 129(5):307-18. PubMed ID: 24117192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the revised Addenbrooke's Cognitive Examination (ACE-R) for detecting mild cognitive impairment and dementia in a Japanese population.
    Yoshida H; Terada S; Honda H; Kishimoto Y; Takeda N; Oshima E; Hirayama K; Yokota O; Uchitomi Y
    Int Psychogeriatr; 2012 Jan; 24(1):28-37. PubMed ID: 21843399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort.
    Hobson P; Meara J
    Int J Geriatr Psychiatry; 2015 Oct; 30(10):1048-55. PubMed ID: 25676160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.